Comparing Sinovac Biotech (SVA) and Its Competitors
Sinovac Biotech (NASDAQ: SVA) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Sinovac Biotech to similar businesses based on the strength of its profitability, risk, valuation, analyst recommendations, institutional ownership, dividends and earnings.
This is a breakdown of recent ratings for Sinovac Biotech and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Sinovac Biotech Competitors||121||768||1644||59||2.63|
As a group, “Biopharmaceuticals” companies have a potential upside of 130.10%. Given Sinovac Biotech’s competitors higher probable upside, analysts plainly believe Sinovac Biotech has less favorable growth aspects than its competitors.
Earnings and Valuation
This table compares Sinovac Biotech and its competitors revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Sinovac Biotech Competitors||$604.20||$110.82||-6.00|
Sinovac Biotech’s competitors have higher revenue and earnings than Sinovac Biotech. Sinovac Biotech is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Sinovac Biotech has a beta of 0.1, indicating that its share price is 90% less volatile than the S&P 500. Comparatively, Sinovac Biotech’s competitors have a beta of 1.18, indicating that their average share price is 18% more volatile than the S&P 500.
This table compares Sinovac Biotech and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sinovac Biotech Competitors||-13,405.03%||38.07%||-20.59%|
Institutional and Insider Ownership
30.7% of Sinovac Biotech shares are owned by institutional investors. Comparatively, 44.9% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 14.9% of shares of all “Biopharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Sinovac Biotech competitors beat Sinovac Biotech on 7 of the 9 factors compared.
Sinovac Biotech Company Profile
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company’s pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.
Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.